Table Of ContentThe Chemotherapy Source Book 3rd edition (September 15, 2001): by Michael C.,
Md. Perry (Editor) By Lippincott Williams & Wilkins Publishers
By OkDoKeY
The Chemotherapy Source Book
Contents
Commonly Used Chemotherapeutic Drugs
Editor
Contributing Authors
Preface
SECTION I
Principles of Chemotherapy
PART A: SCIENTIFIC FOUNDATION OF CHEMOTHERAPY
Chapter 1. Scientific Basis of Cancer Chemotherapy
James K. Schwarz and John W. Yarbro
Chapter 2. Antineoplastic Drug Development
Robert I. Haddad and David A. Van Echo
Chapter 3. Principles of Pharmacology
Antonius A. Miller, Mark J. Ratain, and Richard L. Schilsky
Chapter 4. Norton-Simon Hypothesis
Teresa A. Gilewski and Larry Norton
Chapter 5. Drug Resistance
James H. Goldie
Chapter 6. Adjuvant Chemotherapy
Andrew M. Evens and Jacob D. Bitran
Chapter 7. Combination Chemotherapy
Howard A. Burris III
Chapter 8. Combined Modality Therapy
Mark P. Bryer
Chapter 9. Design and Interpretation of Clinical Trials
Richard Simon and Michael A. Friedman
Chapter 10. Clinical Trials
Barbara K. Barrett
Chapter 11. Hematopoietic Growth Factors
Jeffrey Crawford and Susan Blackwell
Chapter 12. Biologic Response Modifiers: Principles of Biotherapy
Ashok Beedassy and Howard Ozer
Chapter 13. Circadian Timing of Cancer Chemotherapy
Patricia A. Wood and William J. M. Hrushesky
PART B: ROUTES OF ADMINISTRATION
Chapter 14. Intraventricular and Intrathecal Therapy
Arthur Forman and Victor A. Levin
Chapter 15. Intraperitoneal Chemotherapy
Maurie Markman
Chapter 16. Continuous Intravenous Infusion Chemotherapy
Robert W. Carlson
Chapter 17. Intraarterial Therapy
William D. Ensminger
Chapter 18. Perfusion Therapy
Michael S. Sabel and William G. Kraybill
Chapter 19. Hematopoietic Stem Cell Transplantation
Steven Z. Pavletic and James O. Armitage
SECTION II
Chemotherapeutic Drugs
Chapter 20. Covalent DNA-Binding Drugs
Louise B. Grochow
Chapter 21. Antimetabolites
John C. Gutheil and Deborah M. Finucane
Chapter 22. Antitumor Antibiotics and Related Compounds
Charles E. Riggs, Jr.
Chapter 23. Microtubule-Targeting Drugs
Eric Keith Rowinsky and Anthony W. Tolcher
Chapter 24. DNA Topoisomerase II Inhibitors
Anthony W. Tolcher and Eric Keith Rowinsky
Chapter 25. Topoisomerase I–Targeting Drugs
Eric Keith Rowinsky and Anthony W. Tolcher
Chapter 26. Differentiation Agents
Raymond P. Warrell, Jr.
Chapter 27. Hormones
Robert S. DiPaola, Michael Reiss, and Joseph Aisner
Chapter 28. L-Asparaginase
Alan P. Lyss
Chapter 29. Investigational Drugs
Daniel R. Budman and Varun Gupta
Chapter 30. Antibodies
Haleem J. Rasool
SECTION III
Management of Drug Toxicity
Chapter 31. Hematologic Complications of Cancer Chemotherapy
Rasa L. Buntinas and Raymond J. Hohl
Chapter 32. Oral Toxicity
Douglas E. Peterson and Mark M. Schubert
Chapter 33. Dermatologic Toxicity
Antoinette F. Hood and Matthew C. Reeck
Chapter 34. Extravasation
Gerald H. Clamon
Chapter 35. Hypersensitivity Reactions
Raymond B. Weiss
Chapter 36. Ocular Side Effects of Chemotherapy
Linda J. Burns
Chapter 37. Cardiotoxicity of Chemotherapeutic Drugs
Michael S. Ewer and Robert S. Benjamin
Chapter 38. Chemotherapy-Associated Lung Injury
James M. Hinson, Jr. and Andrew W. McKibben
Chapter 39. Gastrointestinal Complications of Chemotherapy
Dayna S. Early
Chapter 40. Hepatotoxicity of Chemotherapeutic Agents
Paul D. King and Michael C. Perry
Chapter 41. Renal and Electrolyte Abnormalities Due to Chemotherapy
William P. Patterson and Garry P. Reams
Chapter 42. Neurotoxicity of Chemotherapy Agents
Michael A. Meyer
Chapter 43. Vascular Toxicity
Donald C. Doll
Chapter 44. Second Malignancies after Chemotherapy
John D. Boice, Jr.
Chapter 45. Chemotherapy in Pregnancy
Irfan Maghfoor and Donald C. Doll
Chapter 46. Gonadal Complications and Teratogenicity of Cancer Therapy
Catherine E. Klein
SECTION IV
Drug Administration
Chapter 47. Central Venous Access for Chemotherapy
Steven B. Standiford
Chapter 48. Risks of Handling Cytotoxic Drugs
Bruce R. Harrison
Chapter 49. Patient Education
Mary H. Johnson and Verna A. Rhodes
SECTION V
Current Therapy of Specific Solid Tumors
Chapter 50. Chemotherapy of Melanoma
Clay M. Anderson
Chapter 51. Chemotherapy of Primary Brain Tumors
Susanne M. Arnold and Roy A. Patchell
Chapter 52. Chemotherapy of Head and Neck Cancer
Everett E. Vokes and Gary S. Gordon
Chapter 53. Chemotherapy of Lung Cancer
Jimmy J. Hwang and Chandra P. Belani
Chapter 54. Chemotherapy of Breast Cancer
Carl G. Kardinal and John T. Cole
Chapter 55. Chemotherapy of Gastrointestinal Cancer
James E. Wooldridge
Chapter 56. Chemotherapy of Endocrine Tumors
John L. Visconti, Alan B. Silverberg, and Kent R. Wehmeier
Chapter 57. Chemotherapy of Genitourinary Cancers
Christopher W. Ryan and Nicholas J. Vogelzang
Chapter 58. Chemotherapy of Gynecologic Cancer
Jeffrey D. Bloss and James Tate Thigpen
Chapter 59. Chemotherapy of Sarcomas of Bone and Soft Tissue
Haralambos Raftopoulos and Karen Antman
Chapter 60. Chemotherapy of Carcinoma of Unknown Primary Site
John D. Hainsworth and F. Anthony Greco
Chapter 61. Chemotherapy of Pediatric Solid Tumors
Donald K. Strickland
SECTION VI
Chemotherapy of Hematologic Malignancies
Chapter 62. Chemotherapy of Hodgkin’s Disease
Bruce A. Peterson
Chapter 63. Chemotherapy of Non–Hodgkin’s Lymphoma
Philip J. Bierman and James O. Armitage
Chapter 64. Chemotherapy of Acute Leukemia in Adults
Charles F. Eisenbeis and Richard A. Larson
Chapter 65. Chemotherapy and Immunotherapy of Chronic Lymphocytic Leukemia and Hairy Cell Leukemia
John C. Byrd and Kanti R. Rai
Chapter 66. Chemotherapy of the Myelodysplastic Syndromes
Bruce D. Cheson
Chapter 67. Management of Chronic Myeloproliferative Disorders and Chronic Myelocytic Leukemia
Ayalew Tefferi
Chapter 68. Chemotherapy of Multiple Myeloma and Related Plasma Cell Dyscrasias
Haleem J. Rasool and Mehdi Farhangi
Appendices
Chemotherapy Programs
James E. Wooldridge
Common Toxicity Criteria
National Cancer Institute
Appendix I: Adverse Event Module
Appendix II: Infection Module
Appendix III: Performance Status Scales/Scores
Appendix IV: RTOG/EORTC Late Radiation Morbidity Scoring Scheme
Appendix V: BMT-Specific Adverse Events
Appendix VI: BMT Complex/Multicomponent Events
COMMONLY USED CHEMOTHERAPEUTIC DRUGS
Generic Name Trade Name (Manufacturer) Abbreviation
Alitretinoin Panretin (Ligand)
Aldesleukin (IL-2) Proleukin (Chiron) IL-2
Altretamine Hexalen (Medlmmune Oncology) HEX
All-trans-retinoic acid (Tretinoin) Vesanoid (Hoffman-LaRoche) ATRA
Aminoglutethimide Cytadren (Ciba-Geigy) AG
Anagrelide Agrylin (Roberts)
Anastrozole Arimidex (AstraZeneca)
Asparaginase (E. coli) Elspar (Merck) L-Asp
Azathioprine Imuran (Glaxo Wellcome) AZ
Bicalutamide Casodex (AstraZeneca)
Bleomycin Blenoxane (Bristol-Myers Squibb) BLEO
Busulfan Myleran (Glaxo Wellcome) BUS
Capecitabine Xeloda (Roche)
Carboplatin Paraplatin (Bristol-Myers Squibb) CARBO, PP
Carmustine BiCNU (Bristol-Myers Squibb) BCNU
Chlorambucil Leukeran (Glaxo Wellcome) CLB
Cisplatin Platinol (Bristol-Myers Squibb) DDP
Cladribine (2-CDA) Leustatin (Ortho Biotech) CDA
Cyclophosphamide Cytoxan (Mead Johnson) Neosar CTX
(Pharmacia & Upjohn)
Cytarabine Cytosar (Pharmacia & Upjohn) araC
Dacarbazine DTIC-Dome (Bayer) DTIC
Dactinomycin-D Cosmegen (Merck) ACT-D
Daunorubicin (Daunomycin) Cerubidine (Bedford) DNR
Daunorubicin, liposomal DaunoXome (Gilead)
Dexamethasone Decadron (Merck) DEX
Docetaxel Taxotere (Aventis)
Doxorubicin Adriamycin (Pharmacia & Upjohn) ADR
Rubex (Bristol-Myers Squibb)
Doxorubicin, liposomal Doxil (Alza)
Epirubicin Ellence (Pharmacia)
Estramustine Phosphate Emcyt (Pharmacia) EP
Etoposide(VP-16-213) VePesid (Bristol-Myers-Squibb) VP-16
Exemestane Aromasin (Pharmacia)
Floxuridine (Roche) FUDR
5-Fluorouracil Fluorouracil (Roche) Adrucil 5-FU
(Pharmacia & Upjohn)
Fludarabine Fludara (Berlex) FDA
Fluoxymesterone Halotestin (Pharmacia & Upjohn) HALO
Flutamide Eulexin (Shering) FLU
Gemcitabine Gemzar (Lilly) GEM
Gemtuzmab Mylotarg (Wyeth-Ayerst)
Goserelin Acetate Zoladex (AstraZeneca) ZOL
Hydroxyurea Hydrea (Bristol-Myers Squibb) HU
Generic Name Trade Name (Manufacturer) Abbreviation
Idarubicin Idamycin (Pharmacia & Upjohn) IDA
Ifosfamide Ifex (Bristol-Myers Squibb) IFX
Imatmib Mesylate Gleevec (Novartis) ST1-S71
Irinotecan Camptosar (Pharmacia & Upjohn) IRI
a-Interferon Intron A (Schering) a-IFN
Roferon A (Roche)
Letrozole Femara (Novartis)
Leuprolide Acetate Lupron (TAP) LU
Levamisole HCl Ergamisol (Janssen) LEV
Lomustine CeeNU (Bristol-Myers Squibb) CCNU
Megestrol Acetate Megace (Bristol-Myers Squibb) MEG
Melphalan (L-phenylalanine Alkeran (Glaxo Wellcome) L-PAM
mustard)
6-Mercaptopurine Purinethol (Glaxo Wellcome) 6MP
Methotrexate Methotrexate (Immunex) MTX
Mexate (Bristol-Myers Squibb)
Methoxsalen (8-MOP) ICN
Mitomycin-C Mutamycin (Bristol-Myers-Squibb) MITO
Mitotane Lysodren (Bristol-Myers Squibb) LYS
Mitoxantrone Novantrone (Immunex) NOV
Nilutamide Nilandron (Hoechst Marion Roussel)
Nitrogen Mustard Mustargen (Merck) HN
2
(Mechlorethamine hydrochloride)
Octreotide Sandostatin (Novartis) SAND
Paclitaxel Taxol (Bristol-Myers Squibb) TAX
Pegaspargase Oncospar (Aventis) PEG
Pentostatin (2'deoxycoformycin) Nipent (Warner-Lambert) PEN
Plicamycin Mithracin (Miles) MITH
Porfimer Photofrin (Sanofi)
Prednisone Prednisone (Various) PRED
Procarbazine Matulane (Roche) PCZ
Rituximab Rituxan (IDEC, Genentech)
Streptozotocin Zanosar (Pharmacia & Upjohn) STN
Tamoxifen Nolvadex (AstraZeneca) TMX
Teniposide (VM-26) Vumon (Bristol-Myers Squibb) VM-26
6-Thioguanine Tabloid-6 Thioguanine (Glaxo 6TG
Wellcome)
Thalidomide Thalomid (Calgene)
Thiotepa Thiotepa (Immunex) TT
Topotecan Hycamtin (SmithKline Beecham) TOPO
Toremifene Fareston (Schering)
Trastuzumab Herceptin (Genentech)
Trimetrexate Neutrexin (Medlmmune Oncology) TriMTX
Vinblastine Velban (Lilly) VLB
Vincristine Oncovin (Lilly) VCR
Vinorelbine Navelbine (Glaxo Wellcome) NVB
Edited By
Michael C. Perry, M.D., M.S., F.A.C.P.
Professor of Internal Medicine
Nellie B. Smith Chair of Oncology
Director, Division of Hematology and Medical Oncology
University of Missouri–Columbia School of Medicine
Ellis Fischel Cancer Center
Columbia, Missouri
Contributing Authors
Joseph Aisner, M.D.
Professor of Medicine and Environmental and Community Medicine
Department of Medicine
Chief, Division of Oncology
University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical
School
The Cancer Institute of New Jersey
New Brunswick, New Jersey
Clay M. Anderson, M.D.
Assistant Professor
Department of Medicine
Division of Hematology and Oncology
University of Missouri–Columbia School of Medicine
Ellis Fischel Cancer Center
Columbia, Missouri
Karen Antman, M.D.
Wu Professor of Medicine
Columbia University College of Physicians and Surgeons
Chief, Division of Medical Oncology
Director, Herbert Irving Comprehensive Cancer Center
New York, New York
James O. Armitage, M.D.
Dean and Professor
College of Medicine
University of Nebraska Medical Center
Omaha, Nebraska
Susanne M. Arnold, M.D.
Assistant Professor of Medicine
Department of Internal Medicine
Division of Hematology and Oncology
University of Kentucky College of Medicine
Markey Cancer Center
Lexington, Kentucky
Barbara K. Barrett, M.S., C.C.R.P.
Research Manager
Department of Internal Medicine
University of Missouri–Columbia School of Medicine
Ellis Fischel Cancer Center
